|
 
Based on current COVID-19 trends, the U.S. Food and Drug Administration (FDA) decided that Wednesday, March 22, 2023, will be the last virtual town hall on test development and validation during the mpox and COVID-19 public health emergencies. Over the last three years, the FDA hosted more than 100 virtual town halls on test development and validation to provide information and answer questions about COVID-19 and mpox tests. If you continue to have questions about test development and validation, please email COVID19Dx@fda.hhs.gov or MPXDx@fda.hhs.gov. The FDA may schedule ad hoc webinars on special topics in the future.
Panelists on March 22 from 12:05 to 1 p.m. ET include:
- Timothy Stenzel, M.D., Ph.D., Director of the Office of In Vitro Diagnostics
- Toby Lowe, Associate Director for Regulatory Programs, Office of In Vitro Diagnostics
- Kristian Roth, Ph.D., Deputy Director of the Division of Microbiology Devices, Office of In Vitro Diagnostics
- Noel Gerald, Ph.D., Branch Chief for Bacterial Respiratory and Medical Countermeasures, Office of In Vitro Diagnostics
There will be an opportunity to ask questions live on the call, and questions may also be submitted in advance by emailing CDRHWebinars@fda.hhs.gov.
- Submit questions by 12 p.m. ET on Monday, March 20, 2023.
- In the subject line of the email, type “Questions for the Virtual Town Hall Series - Test Development and Validation During Public Health Emergencies”. Please specify in your email if your question is for mpox, COVID-19, or both.
If you cannot attend the live virtual town hall, the recording and transcript will be available at CDRH Learn
No registration is required.
|
|
|
|
